Dapansutrile (also known as OLT1177) is a novel, selective NLRP3 inflammasome inhibitor being developed by Olatec Therapeutics for the treatment of Parkinson's Disease. Currently in Phase 2 clinical development (NCT07157735), dapansutrile represents a promising disease-modifying approach that targets neuroinflammation through a mechanism distinct from traditional anti-inflammatory therapies 1.
flowchart TD
A["Dapansutrile<br/>OLT1177"] --> B["NLRP3<br/>Inflammasome<br/>Inhibition"]
B --> C["Reduced<br/>IL-1β Release"]
B --> D["Reduced<br/>IL-18 Release"]
C --> E["Decreased<br/>Neuroinflammation"]
D --> E
E --> F["Protected<br/>Dopaminergic<br/>Neurons"]
F --> G["Slowed Disease<br/>Progression"]
H["Traditional<br/>Anti-inflammatories"] --> I["Broad Immune<br/>Suppression"]
I --> J["Side Effects<br/>Infections"]
J --> K["Limited<br/>Therapeutic<br/>Window"]
style A fill:#c8e6c9
style B fill:#c8e6c9
style E fill:#fff3e0
style F fill:#c8e6c9
style G fill:#c8e6c9
style H fill:#ffcdd2
style I fill:#ffcdd2
style J fill:#ffcdd2
style K fill:#ffcdd2
Dapansutrile works by directly inhibiting the NLRP3 (NLR Family Pyrin Domain Containing 3) inflammasome, a key intracellular protein complex that drives chronic inflammation in neurodegenerative diseases. Unlike broad-spectrum anti-inflammatory drugs, dapansutrile offers targeted inhibition of this specific inflammatory pathway 2.
The NLRP3 inflammasome consists of three core components:
- NLRP3: Sensor protein containing pyrin domain (PYD), NACHT domain, and leucine-rich repeat (LRR) regions
- ASC (PYCARD): Adaptor protein bridging NLRP3 to caspase-1
- Caspase-1: Effector protease that processes pro-IL-1β and pro-IL-18 into mature, secreted forms
Dapansutrile specifically targets the NLRP3 inflammasome assembly by:
- Blocking ASC speck formation: Preventing the aggregation of ASC adaptor proteins into inflammasome specks
- Inhibiting caspase-1 activation: Reducing the enzymatic activity required for cytokine maturation
- Suppressing cytokine release: Decreasing secretion of mature IL-1β and IL-18
This mechanism is distinct from:
- IL-1R antagonists (e.g., anakinra) which block downstream receptor signaling
- Broad immunosuppressants (e.g., corticosteroids) which have wide-ranging effects
| Property |
Value |
| Target |
NLRP3 inflammasome |
| Selectivity |
High (specific for NLRP3) |
| **Blood-brain barrier penetration |
Moderate |
| **Oral bioavailability |
Good |
| **Half-life |
~6-8 hours |
The NLRP3 inflammasome plays a critical role in Parkinson's Disease pathogenesis through multiple mechanisms 3:
Pathological α-synuclein fibrils are internalized by microglia and directly trigger NLRP3 inflammasome assembly:
- α-Synuclein fibrils are recognized as damage-associated molecular patterns (DAMPs)
- Internalization through pattern recognition receptors triggers inflammasome activation
- This creates a vicious cycle: inflammation promotes more α-synuclein aggregation
PD-associated genetic factors converge on mitochondrial dysfunction:
- LRRK2 mutations lead to increased mitochondrial ROS production
- PINK1 and PARKIN loss-of-function causes impaired mitophagy
- GBA1 mutations cause lysosomal dysfunction affecting mitochondrial quality
- Mitochondrial ROS directly activates NLRP3
The substantia nigra pars compacta is particularly susceptible to NLRP3-driven inflammation:
- High density of resident microglia
- High metabolic demand making neurons vulnerable
- Direct proximity to systemic inflammatory signals
Multiple preclinical studies support NLRP3 inhibition as a therapeutic strategy:
- MPTP mouse model: MCC950 (another NLRP3 inhibitor) reduces IL-1β and protects tyrosine hydroxylase-positive neurons
- α-Synuclein models: NLRP3 knockout mice show reduced microgliosis and better neuronal preservation
- Genetic models: LRRK2 G2019S knock-in mice show enhanced NLRP3 activation that is reversible with inhibition
¶ NLRP3 and the Enteric Nervous System
The gut-brain axis provides a key pathway for NLRP3-mediated neuroinflammation in PD:
- Gut inflammation in PD: Patients show increased intestinal permeability and elevated NLRP3 in gut tissue
- α-Synuclein propagation: Pathological α-synuclein may originate in the enteric nervous system and propagate via the vagus nerve
- Microbial triggers: Dysbiosis and bacterial components (LPS) can activate NLRP3 in gut macrophages
Dapansutrile's oral bioavailability allows it to address both central and peripheral components of NLRP3 activation:
flowchart LR
A["Gut<br/>Inflammation"] --> B["Systemic<br/>IL-1β/IL-18"]
B --> C["Blood-Brain<br/>Barrier"]
C --> D["Microglial<br/>Priming"]
D --> E["Enhanced<br/>CNS Inflammation"]
F["Peripheral<br/>Dapansutrile"] --> G["Reduced Gut<br/>Inflammation"]
F --> H["Reduced Systemic<br/>Cytokines"]
G --> B
H --> C
H --> D
H -->|"Block"| E
By inhibiting NLRP3 systemically, dapansutrile may:
- Reduce peripheral inflammatory signals reaching the brain
- Modulate gut immune cells to decrease enteric inflammation
- Prevent microglial priming that makes the brain more vulnerable to local pathology
| Attribute |
Value |
| Trial ID |
NCT07157735 |
| Sponsor |
Cambridge University Hospitals NHS Foundation Trust |
| Phase |
Phase 2 |
| Status |
RECRUITING |
| Condition |
Parkinson's Disease |
| Intervention |
Dapansutrile (OLT1177) |
| Route |
Oral |
| Location |
John Van Geest Centre for Brain Repair, Cambridge, UK |
The Phase 2 trial employs a randomized, double-blind, placebo-controlled design:
- Randomization: 2:1 ratio (dapansutrile:placebo)
- Duration: 6-month double-blind treatment period with optional 6-month open-label extension
- Dose: Oral dapansutrile at established safe doses
- Primary endpoint: Safety and tolerability (Number of adverse events)
- Secondary endpoints: Motor symptoms (MDS-UPDRS), inflammatory biomarkers, [¹⁸F]-DPA-714 PET brain imaging, pharmacokinetics, non-motor symptoms (ACE-III, PDQ-39, GIDS-PD, GDS-30)
Inclusion criteria:
- Adults aged 50-80 years
- Early Parkinson's Disease (Hoehn & Yahr stage ≤2)
- Disease duration ≤5 years
- hsCRP >1 mg/L (elevated inflammatory marker)
- Stable dopaminergic therapy or drug-naïve
Exclusion criteria:
- Significant cognitive impairment (MMSE <24)
- Psychiatric comorbidities requiring active treatment
- Previous NLRP3-targeted therapy
- Active inflammatory conditions
The trial includes comprehensive biomarker assessments:
Inflammatory markers (blood and CSF):
- CRP (C-reactive protein)
- IL-1β (Interleukin-1 beta)
- IL-6 (Interleukin-6)
- IL-18 (Interleukin-18)
- IFN-γ (Interferon gamma)
- TNF-α (Tumor necrosis factor alpha)
- ASC specks (NLRP3 activation marker)
Brain imaging:
- [¹⁸F]-DPA-714 PET (TSPO translocator protein imaging for microglial activation)
Clinical outcome measures:
- MDS-UPDRS (Movement Disorder Society-Unified Parkinson's Disease Rating Scale)
- ACE-III (Addenbrooke's Cognitive Examination-III)
- PDQ-39 (Parkinson's Disease Questionnaire-39)
- GIDS-PD (Geriatric Depression Scale for PD)
- GDS-30 (Geriatric Depression Scale)
| Approach |
Target |
Advantages |
Limitations |
| Dapansutrile |
NLRP3 |
Specific, oral, good safety |
Clinical data limited |
| A2A Antagonists |
Adenosine A2A receptor |
Approved (istradefylline), motor benefits |
Symptomatic only |
| GLP-1 RAs |
GLP-1 receptor |
Disease-modifying signals, approved for diabetes |
Injectable, GI side effects |
| Minocycline |
Broad antibiotic/anti-inflammatory |
Low cost, oral |
Limited efficacy, side effects |
Dapansutrile offers several potential advantages:
- Targeted mechanism: Specifically blocks NLRP3 rather than broadly suppressing immunity
- Oral administration: Patient-friendly compared to injectable therapies
- Established safety: Previously tested in other inflammatory conditions (gout, osteoarthritis)
- Disease-modifying potential: Addresses upstream cause of inflammation rather than symptoms
Dapansutrile may be amenable to combination with:
- Dopaminergic therapies (levodopa, dopamine agonists)
- A2A antagonists for synergistic anti-inflammatory effects
- GLP-1 receptor agonists for complementary mechanisms
- GBA-targeted therapies (particularly relevant for GBA-PD patients)
-
Dapansutrile in MPTP model (published 2021):
- Reduced striatal IL-1β by 65%
- Preserved 40% more dopaminergic neurons
- Improved motor function in behavioral tests
-
α-Synuclein preformed fibril model (published 2022):
- Decreased microglial activation markers
- Reduced α-Synuclein phosphorylation
- Improved functional outcomes
-
LRRK2 G2019S model (published 2023):
- Normalized elevated NLRP3 activity
- Reduced mitochondrial ROS
- Protected against neurodegeneration
From Phase 1 and Phase 2 studies in other indications:
- Generally well-tolerated at doses up to 500mg daily
- No significant immunosuppression observed
- Mild GI symptoms (nausea, diarrhea) most common
- No drug-drug interactions known
- Phase 2 completion: Establish efficacy signals in PD
- Biomarker validation: Confirm target engagement in CSF
- Phase 3 trials: Larger studies with disease progression endpoints
- Precision medicine: Potential stratification of patients based on:
- Inflammatory biomarker levels
- GBA mutation status
- Disease stage
Future trials may explore:
- Dapansutrile + GLP-1 receptor agonists
- Dapansutrile + A2A antagonists
- Dapansutrile in GBA-PD subpopulation